FDA revises antidepressant black boxes
This article was originally published in Pharmaceutical Approvals Monthly
Class labeling for antidepressants is updated Aug. 2 to include warnings about increased risks of suicidality in young adults ages 18 to 24. The new language, which FDA proposed in May, states that risk was not seen in adults older than 24 and that the risk decreased for adults ages 65 and older. Also added is a statement that "Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide." The Psychopharmacologic Drugs Advisory Committee recommended the changes at a 2006 meeting on the risk of drug-related suicidality in adults. The black box warning on suicidality in pediatric patients was first added in 2005...
You may also be interested in...
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.
Entries are now open for the Global Generics & Biosimilars Awards 2021, which will take place in Milan, Italy on 10 November.
Bharat Biotech’s COVID-19 vaccine has shown 80.6% efficacy in interim data from Phase III clinical trials, slightly better than the 79.3% reported by Sinopharm and significantly higher than Sinovac’s 50.6% for their vaccines based on similar technology. Supply deals are already on the way, with Brazil having signed up for 200 million doses.